12 results about "Chronic rhinosinusitis" patented technology

The present disclosure relates to pharmaceutical compositions comprising from about 100 mg to about 300 mg of an antigen binding protein which binds to IL-5. Compositions and antigen binding proteins of the disclosure are useful in the treatment of IL-5 mediated diseases, such as EGPA, HES, CRSsNP and CRSwNP, and can be administered about once every 6 months.

150mg / mL omalizumab formulation for use in a method of treatment of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, wherein the omalizumab is administered subcutaneously by a syringe.

The present disclosure relates to succinic acid or a pharmaceutically acceptable salt thereof for use in the treatment of chronic rhinosinusitis.

150mg / mL omalizumab formulation for use in a method of treatment of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, wherein the omalizumab is administered subcutaneously by a syringe.

A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg / mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.

A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg / mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.

The application discloses a method for stereoscopic reconstruction and visualization of nasal polyp tissue based on artificial intelligence recognition of continuous pathological sections, which comprises the following steps: strict continuous section of a reconstruction object; HE staining of the continuous sections; affine registration of the continuous pathological sections; one-by-one analysis of the registered continuous pathological sections; stacking according to the registration sequence, then processing, to obtain three-dimensional model data of the nasal polyp tissue structure; and visual rendering of the three-dimensional model data of the nasal polyp tissue structure, combined with a preliminary stereoscopic model, to obtain a final stereoscopic model of the nasal polyp tissue structure. The method can reconstruct and visualize the nasal polyp tissue, and can show the three-dimensional structure of the distribution characteristics of inflammatory cells and tissue structure of the nasal polyp in the spatial structure, so that the morphological structure content of the nasal polyp tissue is enriched, and morphological basis is provided for further exploring the occurrence and development mechanism of chronic rhinosinusitis with nasal polyps.

150 mg / mL omalizumab formulation for use in a method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled 5 corticosteroids, wherein the omalizumab is administered subcutaneously by a syringe. Omalizumab formulation is prefilled as 0.5, 1 and a new 2 mL volume in a new prefilled syringe (Fig.6), said syringe having improved properties over the prior art syringe, such as: a higher gauge, increased inner diameter and reduced break loose force. Overall, the new prefilled syringes offer improved patient convenience and experience: fewer injections may be necessary to meet a dose requirement (Fig.17), also meaning a lower chance of an injection site reaction; expelling times are reduced (Fig.16); and injection pain is reduced.

The present disclosure relates to methods for treating chronic rhinosinusitis with a composition comprising an effective amount of a N-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamide DPP1 inhibitor compound of Formula (I) or a pharmaceutically acceptable salt thereof. In one embodiment, the compound of Formula (I) is (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihyd ro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (brensocatib).

The present invention relates to the technical field of disease model construction, in particular to a method for constructing a non-human primate chronic rhinosinusitis model. The method comprises the step of placing an expansive sponge in the nasal meatus of the non-human primate. The method does not require any special instrument device, and has low costs. By means of the construction of the present invention, a chronic rhinosinusitis model is successfully constructed in a non-human primate for the first time, which lays the foundation for exploring the occurrence and development of rhinosinusitis, fills the technical gap in existing rhinosinusitis model construction, and has great clinical value and economic value.

The present disclosure, relates, in general, to methods of treating chronic rhinosinusitis, with or without nasal polyps, using an antibody specific for thymic stromal lymphopoietin (TSLP).

Described herein are compositions, methods, kits and devices for the treatment and / or prevention upper respiratory tract conditions, including sinusitis. In particular, bacterial populations described herein are live, purified bacteria for the modulation, restoration and / or promotion of the microbiome in the upper respiratory tract of a subject, including the nasal cavity, to promote health. Such bacterial populations may include single or multiple strains for bacteria. The multiple strains of bacteria may be strains from the same or different species, including species of Corynebacterium and / or Dolosigranulum pigrum.